2024/10/18 17:25:15 | |
---|---|
Price | |
209.30 EUR | |
Difference | -0.29% (-0.60) |
ISIN | DK0010272202 |
Symbol | GMAB |
Exchange | Hanover |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 13,299 EUR |
Benchmark | OMX COPENHAGEN 20 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 211.50 EUR |
High | 211.50 EUR |
Low | 209.30 EUR |
Close (prev. day) | 209.90 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 4 |
Last size | 0 |
Related Futures | 9 |
Related Options | - |
Date | Headline | Download | |
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings |
2024/10/18 17:25:15 | |
---|---|
Price | |
209.30 EUR | |
Difference | -0.29% (-0.60) |
ISIN | DK0010272202 |
Symbol | GMAB |
Exchange | Hanover |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 13,299 EUR |
Benchmark | OMX COPENHAGEN 20 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 211.50 EUR |
High | 211.50 EUR |
Low | 209.30 EUR |
Close (prev. day) | 209.90 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 4 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -22.31% | -30.33% | -45.17% |
Perf (abs.) | -60.10 | -91.10 | -172.40 |
Beta | 0.20 | 0.27 | 0.62 |
Volatility | 27.93 | 30.75 | 33.18 |
Ø price 5 days | Ø volume 5 days (pcs.) | 210.60 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 222.10 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 239.17 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 259.90 EUR (0) |
YTD High | date | 295.90 EUR (2024/01/09) |
YTD Low | date | 206.90 EUR (2024/10/16) |
52 Weeks High | date | 300.20 EUR (2023/11/14) |
52 Weeks Low | date | 206.90 EUR (2024/10/16) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Vienna Stock Exchange | 2024/10/18 | 17:32 | 210.30 EUR | 0.00 | 5 |
Tradegate | 2024/10/18 | 22:26 | 209.70 EUR | 0.01 | 10 |
Stuttgart | 2024/10/18 | 08:07 | 211.30 EUR | 0.00 | 3 |
Nasdaq Copenhagen | 2024/10/18 | 17:20 | 1,563.50 DKK | 143.68 | 2,548 |
Munich | 2024/10/18 | 08:05 | 210.20 EUR | 0.00 | 2 |
London Stock Exchange European Trade Reporting | 2024/10/18 | 16:55 | 1,559.75 DKK | 0.00 | 2 |
Hanover | 2024/10/18 | 17:25 | 209.30 EUR | 0.00 | 4 |
Frankfurt | 2024/10/18 | 10:14 | 212.10 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/10/18 | 21:44 | 232.31 USD | 0.14 | 21 |
Duesseldorf | 2024/10/18 | 19:31 | 208.30 EUR | 0.00 | 7 |
Berlin | 2024/10/18 | 19:35 | 210.00 EUR | 0.00 | 16 |
GENMAB A/S |
- - |
Carl Jacobsens Vej 30, Valby - 2500 Copenhagen |
Telefon: +45-70-20-27-28 |
Fax: + |
E-mail: info@genmab.com |
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark. |
Jan G. J. van de Winkel | Chairman of Managing Board |
Judith Klimovsky | Member of Executive Committee |
Martine J. van Vugt | Member of Executive Committee |
Anthony Mancini | Member of Executive Committee |
Anthony Pagano | Member of Executive Committee |
Birgitte Stephensen | Member of Executive Committee |
Christopher Cozic | Member of Executive Committee |
Tahamtan Ahmadi | Member of Executive Committee |
Deirdre Connelly | Chairman of Supervisory Board |
Anders Gersel Pedersen | Member of Supervisory Board |
Mijke Zachariasse | Member of Supervisory Board |
Paolo Augusto Paoletti | Member of Supervisory Board |
Elizabeth O'Farrell | Member of Supervisory Board |
Martin Schultz | Member of Supervisory Board |
Pernille Erenbjerg | Member of Supervisory Board |
Rolf K. Hoffmann | Member of Supervisory Board |
Takahiro Hamatani | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer